ID905B - PROVISIONS CONTAIN STABLED GONADOTROPINS - Google Patents
PROVISIONS CONTAIN STABLED GONADOTROPINSInfo
- Publication number
- ID905B ID905B IDP219492A ID922194A ID905B ID 905 B ID905 B ID 905B ID P219492 A IDP219492 A ID P219492A ID 922194 A ID922194 A ID 922194A ID 905 B ID905 B ID 905B
- Authority
- ID
- Indonesia
- Prior art keywords
- preparations
- lyophilized
- dicarboxylic acid
- disclosed
- contain
- Prior art date
Links
- 102000006771 Gonadotropins Human genes 0.000 title abstract 2
- 108010086677 Gonadotropins Proteins 0.000 title abstract 2
- 239000002622 gonadotropin Substances 0.000 title abstract 2
- 229940094892 gonadotropins Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 5
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 abstract 3
- 235000018102 proteins Nutrition 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 150000001510 aspartic acids Chemical class 0.000 abstract 1
- 235000015165 citric acid Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000002840 non-reducing disaccharides Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed are lyophilized gonadotropin containing preparations containing a dicarboxylic acid salt stabilizer. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with, and at least partially capable of stabilization by, the particular stabilizer in lyophilized form. The preparations contain a sufficient amount of dicarboxylic acid salt to stabilize the protein in freeze-dried form for a desired time at a desired temperature. Typical dicarboxylic acid salts disclosed are the salts of citric, tartaric, and aspartic acids. The preparations preferably include a non-reducing disaccharide to increase the collapse temperature of the solution to be lyophilized. Methods of making the preparations in lyophilized form and the resulting injectable preparations are also disclosed. <IMAGE>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP90200665 | 1990-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID905B true ID905B (en) | 1996-09-10 |
Family
ID=8204967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDP219492A ID905B (en) | 1990-03-20 | 1992-01-31 | PROVISIONS CONTAIN STABLED GONADOTROPINS |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0448146B1 (en) |
| JP (1) | JP3031570B2 (en) |
| KR (1) | KR100221123B1 (en) |
| AT (1) | ATE107172T1 (en) |
| AU (1) | AU631730B2 (en) |
| CA (1) | CA2037884C (en) |
| DE (1) | DE69102465T2 (en) |
| DK (1) | DK0448146T3 (en) |
| ES (1) | ES2057731T3 (en) |
| FI (1) | FI101194B1 (en) |
| ID (1) | ID905B (en) |
| IE (1) | IE64738B1 (en) |
| NZ (1) | NZ237458A (en) |
| PT (1) | PT97074B (en) |
| ZA (1) | ZA911659B (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1250075B (en) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | PHARMACEUTICAL COMPOSITIONS CONTAINING GONADOTROPINE. |
| ES2098140T3 (en) * | 1993-04-28 | 1997-04-16 | Akzo Nobel Nv | LIOSPHERES CONTAINING GONADOTROPIN. |
| JP4165878B2 (en) * | 1993-06-03 | 2008-10-15 | 株式会社林原生物化学研究所 | Trehalose-releasing enzyme, its production method and use |
| US5556771A (en) * | 1995-02-10 | 1996-09-17 | Gen-Probe Incorporated | Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification |
| AU707796B2 (en) * | 1995-03-21 | 1999-07-22 | Merck Serono Sa | HCG liquid formulations |
| IL120202A (en) | 1996-03-07 | 2001-03-19 | Akzo Nobel Nv | Container with freeze-dried vaccine components |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| KR20010083126A (en) * | 1998-07-23 | 2001-08-31 | 피터 지. 스트링거 | FSH and FSH Variant Formulations, Products and Methods |
| US20030166525A1 (en) | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
| JP2002541213A (en) | 1999-04-13 | 2002-12-03 | インヘール セラピューティック システムズ, インコーポレイテッド | Pulmonary administration of dry powder formulations for the treatment of infertility |
| AU2002210749B2 (en) | 2000-10-31 | 2006-12-21 | Pharma Mar, S.A. | Kahalalide F formulation |
| WO2002053136A1 (en) * | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Sustained release preparations |
| GB0207092D0 (en) * | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| MXPA05010635A (en) | 2003-04-02 | 2005-12-12 | Ares Trading Sa | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant. |
| US20040248784A1 (en) | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| WO2004112826A1 (en) * | 2003-06-20 | 2004-12-29 | Ares Trading Sa | Freeze-dried fsh / lh formulations |
| DE10333317A1 (en) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulation for protein medicines without the addition of human serum albumin (HSA) |
| WO2005113147A2 (en) | 2004-04-08 | 2005-12-01 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| BRPI0707796A2 (en) * | 2006-02-15 | 2011-05-10 | Imclone Systems Inc | formulation and treatment method |
| NZ583991A (en) * | 2007-11-01 | 2012-02-24 | Merck Serono Sa | Luteinizing hormone liquid formulations |
| CN101269215B (en) * | 2008-05-15 | 2011-03-23 | 上海天伟生物制药有限公司 | Glucoprotein incretion composition |
| WO2010132508A2 (en) | 2009-05-11 | 2010-11-18 | Biomatrica, Inc. | Compositions and methods for biological sample storage |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| CA2816575C (en) | 2010-11-05 | 2019-06-11 | Baxter Healthcare S.A. | A new variant of antihemophilic factor viii having increased specific activity |
| CN102293756A (en) * | 2011-08-24 | 2011-12-28 | 蚌埠丰原涂山制药有限公司 | Freeze-dried powder injection of menotropins and preparation method thereof |
| HUE037811T2 (en) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| CN108517010A (en) | 2012-01-27 | 2018-09-11 | 普罗典娜生物科学有限公司 | Identify the humanized antibody of alpha-synapse nucleoprotein |
| UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
| EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | Formulations and methods for stabilizing pcr reagents |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| JP6661554B2 (en) | 2014-06-10 | 2020-03-11 | バイオマトリカ,インク. | Platelet stabilization at ambient temperature |
| JP6827048B2 (en) | 2015-12-08 | 2021-02-10 | バイオマトリカ,インク. | Decreased erythrocyte sedimentation rate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3932943A (en) * | 1970-08-14 | 1976-01-20 | E. I. Du Pont De Nemours And Company | Method of preparation of lyophilized biological products |
| IT1057895B (en) * | 1975-02-17 | 1982-03-30 | Serono Lab | HUMAN CHORIONIC GONADOTROPINE PARALLEL DESALINIZED TO INDUCE OUVULATION |
| DE3467706D1 (en) * | 1983-04-28 | 1988-01-07 | Armour Pharma | Pharmaceutical preparation containing purified fibronectin |
| GB8604983D0 (en) * | 1986-02-28 | 1986-04-09 | Biocompatibles Ltd | Protein preservation |
| US5059587A (en) * | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
-
1991
- 1991-03-05 IE IE73291A patent/IE64738B1/en not_active IP Right Cessation
- 1991-03-06 EP EP91200483A patent/EP0448146B1/en not_active Expired - Lifetime
- 1991-03-06 DE DE69102465T patent/DE69102465T2/en not_active Expired - Lifetime
- 1991-03-06 ZA ZA911659A patent/ZA911659B/en unknown
- 1991-03-06 AT AT91200483T patent/ATE107172T1/en not_active IP Right Cessation
- 1991-03-06 DK DK91200483.5T patent/DK0448146T3/en active
- 1991-03-06 ES ES91200483T patent/ES2057731T3/en not_active Expired - Lifetime
- 1991-03-08 CA CA002037884A patent/CA2037884C/en not_active Expired - Lifetime
- 1991-03-18 FI FI911309A patent/FI101194B1/en active
- 1991-03-18 NZ NZ237458A patent/NZ237458A/en unknown
- 1991-03-19 JP JP3054865A patent/JP3031570B2/en not_active Expired - Lifetime
- 1991-03-19 PT PT97074A patent/PT97074B/en not_active IP Right Cessation
- 1991-03-19 KR KR1019910004303A patent/KR100221123B1/en not_active Expired - Lifetime
- 1991-03-19 AU AU73623/91A patent/AU631730B2/en not_active Expired
-
1992
- 1992-01-31 ID IDP219492A patent/ID905B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI101194B (en) | 1998-05-15 |
| ES2057731T3 (en) | 1994-10-16 |
| PT97074B (en) | 1998-10-30 |
| JP3031570B2 (en) | 2000-04-10 |
| DK0448146T3 (en) | 1994-10-24 |
| IE64738B1 (en) | 1995-09-06 |
| KR910016340A (en) | 1991-11-05 |
| AU631730B2 (en) | 1992-12-03 |
| HK1002494A1 (en) | 1998-08-28 |
| ZA911659B (en) | 1991-12-24 |
| ATE107172T1 (en) | 1994-07-15 |
| AU7362391A (en) | 1991-09-26 |
| DE69102465T2 (en) | 1995-03-02 |
| PT97074A (en) | 1991-10-31 |
| FI101194B1 (en) | 1998-05-15 |
| JPH04217630A (en) | 1992-08-07 |
| FI911309L (en) | 1991-09-21 |
| IE910732A1 (en) | 1991-09-25 |
| DE69102465D1 (en) | 1994-07-21 |
| KR100221123B1 (en) | 1999-09-15 |
| EP0448146A1 (en) | 1991-09-25 |
| NZ237458A (en) | 1992-02-25 |
| FI911309A0 (en) | 1991-03-18 |
| CA2037884C (en) | 2003-10-21 |
| EP0448146B1 (en) | 1994-06-15 |
| CA2037884A1 (en) | 1991-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID905B (en) | PROVISIONS CONTAIN STABLED GONADOTROPINS | |
| TR199800062A2 (en) | Formulations containing liquid gonadotropin. | |
| EP0355460A3 (en) | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization | |
| CA2125855A1 (en) | A stabilized pharmaceutical formulation comprising growth hormone and histidine | |
| ATE248922T1 (en) | HORMONE ANALOGUES WITH MULTIPLE CTP EXTENSIONS | |
| RU98100930A (en) | LIQUID COMPOSITIONS CONTAINING GONADOTROPINE | |
| DE3782737D1 (en) | STABILIZATION OF GROWTH HORMONES. | |
| CA2124801A1 (en) | Gonadotropin containing pharmaceutical compositions with sucrose stabilizer | |
| IL82735A0 (en) | Isolation of bioactive,monomeric growth hormone | |
| US5384132A (en) | Stabilized gonadotropin containing preparations | |
| EP0726076A4 (en) | Method of stabilizing protein c or activated protein c and stabilized composition | |
| US5270057A (en) | Stabilized gonadotropin containing preparations | |
| HUT47374A (en) | Fungicide compositions containing /2-cyano-2-oximino-acetyl/-aminoacid derivatives as active components and process for producing the active components | |
| EP0294668A3 (en) | (2-cyano-2-oximinoacetyl)-amino acid derivatives | |
| Slyvchuk et al. | Stabilizing the gonadotropin activity with the use of organic compounds | |
| KR950704494A (en) | Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV)) | |
| DK661888A (en) | BIOLOGICALLY ACTIVE MOLECULES |